Murine hepatitis virus as a surrogate for studying SARS-CoV-2 in food processing biofilms

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and murine hepatitis virus (MHV) are of the same genus (β coronavirus). Therefore, it is suggested that MHV can be utilized as an excellent persistent surrogate model for SARS-CoV-2. Furthermore, a recent study conducted on wastewater showed no statistically significant difference in the RNA decay of SARS-CoV-2 compared to MHV.

Study: A biosafety level 2 surrogate for studying SARS-CoV-2 survival in food processing environmental biofilms. Image Credit: MotionEmo/ ShutterstockStudy: A biosafety level 2 surrogate for studying SARS-CoV-2 survival in food processing environmental biofilms. Image Credit: MotionEmo/ Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

One of the leading carriers of foodborne pathogens and a significant threat to food safety is the formation of biofilms in food processing facilities. Within food processing facilities, the main focus of research has been fungal and bacterial biofilms, with limited research focussed on viral particles in the mixed-species biofilm community. However, several factors could promote the harboring of SARS-CoV-2 in meat processing facilities, including the temperature meat is stored and the materials of surfaces used in such facilities.

In the context of stability and infectious state of the virus in multi-species biofilms, there is a critical gap in the knowledge. Therefore, researchers from Texas A&M University inoculated MHV (SARS-CoV-2 surrogate) into a meat processing environmental biofilm and developed it on stainless steel (SS), PVC, and tiles at 7°C. The survival of the virus was then analyzed via quantitative polymerase chain reaction (qPCR) and plaque assays to evaluate the survival rates of the viral particles in the environmental biofilms.

A preprint version of this study, which is yet to undergo peer review, is available on the bioRxiv* server.

The study

Drain samples containing environmental microorganisms were developed on a SS chip, a PVC chip, and a tile surface for five days at 7°C with or without MHV. The mean biofilm microbial cells recovered from the SS chip with MHV ranged from 3.5 to 6.0e+6 CFUs/mL, which was a 1.74-fold increase compared to the chip without MHV. From the PVC chip without MHC, the mean biofilm microbial cells recovered ranged from 1.8 to 4.0e+g CFUs/mL, whereas the range of total biofilm microorganisms retrieved from the chip with MHV increased to a range of 5.0 to 7.8e+6 CFUs/mL, which was a 2.1-fold increase. For the tile chip without MHV, the mean biofilm microbial cells recovered ranged from 1.8 to 3.8e+6 CFE/mL, which increased 2.11-fold to 4.8 to 7.0e+6 CFUs/mL for the tile with MHV.

For the qPCR, the biofilm and MHV sample on SS chips had an average critical threshold (CT) of 15.4, whereas the CT for the virus by itself on SS was 14.2. For the biofilm and MHV sample on PVC chips, the CT was 15.6, and for the virus itself on PVC the CT was 14.0. For the biofilm and MHV sample on tile chips, the CT was 22.0, and for MHV by itself, the CT was 21.6.

For the plaque assay results, the biofilm and MHV samples on the SS chips had an average viral particle unit (VPU)/mL of 650VPUs/mL, whereas, for the MHV sample by itself on the SS chips, the VPUs/mL was 4250 VPUs/mL, which was a 6.54-fold difference. For the biofilm MHV samples on the PVC chips, the average VPUs/mL was 600 VPUs/mL, whereas the average VPUs/mL for the virus by itself on the PVC chips was 5500 VPUs/mL, which was a 9.17-fold difference. For the biofilm and MHV samples on the tile chips, the average VPUs/mL was 675 VPUs/mL, whereas the average VPUs/mL for the virus on the tile chips was 6250 VPUs/mL, which was a 9.26-fold difference.

Implications

The results from this study show that environmental multi-species biofilms found in meat processing plants are capable of harboring viral particles, specifically MHV, which was used as a surrogate for SARS-CoV-2. Furthermore, these viral particles can survive for extended periods protecting them from sanitizers. Therefore, this allows for a safe reservoir for the virus to dwell and be dispersed periodically within the meat processing facility, making such facilities a hotspot for increased numbers of SARS-CoV-2 infections.

Future studies conducted on this topic should focus on deciphering the molecular mechanism of how these interactions occur. Gaining this knowledge will help design targeted intervention strategies to reduce the harbourage and spread of viral lodged multi-species biofilms.  

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 8 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Colin Lightfoot

Written by

Colin Lightfoot

Colin graduated from the University of Chester with a B.Sc. in Biomedical Science in 2020. Since completing his undergraduate degree, he worked for NHS England as an Associate Practitioner, responsible for testing inpatients for COVID-19 on admission.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Lightfoot, Colin. (2023, May 08). Murine hepatitis virus as a surrogate for studying SARS-CoV-2 in food processing biofilms. News-Medical. Retrieved on November 24, 2024 from https://www.news-medical.net/news/20211104/Murine-hepatitis-virus-as-a-surrogate-for-studying-SARS-CoV-2-in-food-processing-biofilms.aspx.

  • MLA

    Lightfoot, Colin. "Murine hepatitis virus as a surrogate for studying SARS-CoV-2 in food processing biofilms". News-Medical. 24 November 2024. <https://www.news-medical.net/news/20211104/Murine-hepatitis-virus-as-a-surrogate-for-studying-SARS-CoV-2-in-food-processing-biofilms.aspx>.

  • Chicago

    Lightfoot, Colin. "Murine hepatitis virus as a surrogate for studying SARS-CoV-2 in food processing biofilms". News-Medical. https://www.news-medical.net/news/20211104/Murine-hepatitis-virus-as-a-surrogate-for-studying-SARS-CoV-2-in-food-processing-biofilms.aspx. (accessed November 24, 2024).

  • Harvard

    Lightfoot, Colin. 2023. Murine hepatitis virus as a surrogate for studying SARS-CoV-2 in food processing biofilms. News-Medical, viewed 24 November 2024, https://www.news-medical.net/news/20211104/Murine-hepatitis-virus-as-a-surrogate-for-studying-SARS-CoV-2-in-food-processing-biofilms.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients